This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatology  • Dermatologic Disorders  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Dermatologic Disorders, Other  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Christina Wagner, MD; Henrik Mohme, MD; Tanja Krömer-Olbrisch, MD; Rudolf Stadler, MD; Sergij Goerdt, MD; Hjalmar Kurzen, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Histiocytoses are a heterogeneous group of idiopathic diseases with a localized or disseminated accumulation of histiocytic cells and are classified into Langerhans cell histiocytosis (LCH) and non-Langerhans cell histiocytosis (N-LCH). Lesional cells in LCH are characterized by dendritic cell markers such as S-100 as well as Langerhans cell–specific features such as Birbeck granules and expression of CD1a, langerin, and fascin. Langerhans cell histiocytosis generally occurs during childhood, but an increasing incidence in adults has been reported.¹ Multiorgan LCH is associated with a considerable mortality, and so new treatment options beyond established chemotherapy protocols are needed. Herein, we report 2 cases of LCH that did not respond to imatinib, a kinase inhibitor recently used to treat LCH² and N-LCH.³

Report of Cases

Case 1

A 21-year-old man presented with a 1-year history of painful erosions and papules . . . [Full Text of this Article]

Case 2

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?